Loading clinical trials...
Loading clinical trials...
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
Conditions
Interventions
Pumitamig
Durvalumab
Locations
255
United States
Southern Cancer Center Pc
Daphne, Alabama, United States
Local Institution - 0780
Chandler, Arizona, United States
Local Institution - 0585
Golden, Colorado, United States
Medical Oncology Hematology Consultants, PA
Newark, Delaware, United States
Local Institution - 0711
Ocala, Florida, United States
Local Institution - 0756
Marietta, Georgia, United States
Start Date
March 16, 2026
Primary Completion Date
September 18, 2030
Completion Date
December 31, 2033
Last Updated
April 6, 2026
NCT07510724
NCT06305754
NCT05920356
NCT06128551
NCT07251582
NCT01720836
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions